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Abstract We report prospectively observed risk for
breast cancer in breast cancer kindreds without a demon-
strable BRCA1/2 mutation. According to family history, the
optimal available member(s) of each breast cancer kindred
attending our clinic was tested for BRCA mutations.
Women in families without a demonstrable BRCA mutation
were subjected to annual mammography. BRCA mutations
were demonstrated in 496/2,118 (23 %) breast cancer
kindreds. In families without a demonstrable BRCA
mutation, a total of 3,161 healthy women aged 25–59 years
were prospectively followed for 24,808 observation years.
Sixty-four cancers were observed, compared to 34.0
expected (p \ 0.01), arriving at a 7.9 % cumulative risk at
age 60 compared to 4.0 % in the population [relative risk
(RR) = 2.0]. Women with one mother or sister affected
B50 years and with no other close relatives with breast
cancer did not have increased risk (0 cancers observed and
0.6 expected at age 40, 11 cancers observed and 7.9
expected at age 60, p [ 0.05). Excluding these, cumulative
risk at 60 years was 8.8 % (RR = 2.2). The highest
cumulative risk at 60 years was 11.4 %, found in families
with two cases B55 years (RR = 2.8). In breast cancer
kindreds without a demonstrable BRCA mutation, the risk
for breast cancer in female first degree relatives was about
twice the risk in the general population. Women with one
early affected relative only did not have increased risk for
early onset breast cancer, while those with more than one
young affected relative had close to three times population
risk.
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In cancer genetic clinics, genetic counseling based on
family history of breast cancer and disclosure of results of
genetic testing is the daily routine. In most breast cancer
kindreds, no causative genetic mutation is found. Models to
predict risk are usually based on retrospective studies of
family histories with the intention to select families likely
to have causative BRCA1/2 mutations. Because access to
genetic testing has been the limiting factor, family history
has been used to select families with high probabilities of
BRCA mutations for mutation testing. (For an overview see
Claus [1] and BOADICEA [2].) How these models arrive
at predictive values of risk for breast cancer in women
tested to not have a disease-causing mutation, is not based
on prospective observations and may be influenced by
assumptions. There is limited information based on pro-
spectively observed incidence rates of breast cancer in
adult female relatives to breast cancer patients in breast
cancer kindreds without a demonstrable genetic cause.
The Inherited Cancer Research Group at The Norwegian
Radium Hospital has comprehensive access to the records
of families affected by breast cancer. We have previously
reported that only 23 % of BRCA1 mutation carriers in a
series of incident breast cancers met the family-based
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criteria used to select a patient for BRCA testing [3]. We
here report the prevalence of deleterious BRCA mutations
in breast cancer kindreds meeting these criteria in our out
patient cancer genetic clinics, and the cumulative incidence
rates for breast cancer by age in breast cancer kindreds not
having a demonstrable causative mutation.
Materials and methods
Our team has identified families with breast or breast–
ovarian cancer for more than 20 years from across Norway.
Selection criteria and follow-up protocols were published
and became national guidelines [4]. The later international
guidelines [5] were compatible with our national guide-
lines, which we maintained for our continued activity. The
criteria were: (1) four cases of breast cancer in the family,
(2) two cases = \55 years of age, (3) one case = \60 -
years of age with bilateral breast cancer, (4) one case with
breast and another cancer = \60 years, (5) one case with
breast cancer = \50 years, and (6) one case with breast
and a first degree relative with ovarian cancer or a woman
with both breast and ovarian cancer in the family. In
families meeting one or more of the criteria, first degree
female relatives of breast or ovarian cancer cases were
considered at risk and invited to monitored follow-up.
Second degree relatives through males, were offered health
surveillance as well, but are not included in this report. An
included patient could meet one, some or all these criteria.
When an individual came close to the criteria, the team was
able to exercise discretion and offer testing and follow-up.
Each patient had genetic counseling at our out patient
genetic clinic before inclusion, signed informed consent to
genetic testing, and provided a family tree with the details
of first and second degree relatives including age, sex, and
cancers. In most cases, we obtained medical records to
validate all breast cancer cases in the family and invited all
living close relatives with any cancer to provide blood
samples for genetic testing.
For categorizing all women included according to
family history, we excluded all cases prospectively diag-
nosed during the study. For this report, we initially ana-
lyzed all families without a demonstrable BRCA mutation
as one group, from now on referred to as ‘‘the total series.’’
We decided to analyze four subgroups: (1) at least four
breast cancer cases in the family, (2) at least two breast
cancer cases = \55 years in the family, (3) one breast
cancer case only in the family and that case = \50 years at
onset, and (4) kindreds with both breast and ovarian cancer.
These four subgroups were selected because the experience
was that the groups 1–3 had been the inclusion criteria
most often clinically discussed during the years and group
4 might indicate BRCA mutations overlooked by the
genetic testing and/or the presence of other genes causing
both breast and ovarian cancer not tested for. Also, group 1
was considered indicative of gene(s) with high life-time
penetrance, group 2 was considered indicative of highly
penetrant gene(s) with early onset of disease, and group 3
had been a frequent clinical problem when a young woman
presented herself with a young mother or sister dying or
dead from breast cancer. Also, group 3 would give infor-
mation on recessive inheritance.
The follow-up included annual mammography for
women aged 25 or more. While our study was ongoing,
biennial mammography screening was offered to all
women in the population from 50 to 70 years of age. We
then referred most of our patients past 60 years to the
population screening. We censored the current study at
60 years of age.
Availability of genetic testing has developed over the
years. Initially, we described that the presence of frequent
(founder) BRCA1/2 mutations were responsible for the
majority of the carriers of breast cancer mutations and all
families were tested for these mutations [3]. Later, all kin-
dreds without a demonstrated BRCA1/2 founder mutation
were examined by Sanger sequencing and multiplex liga-
tion-dependent probe amplification (MLPA) of BRCA1/2.
From the onset, we had stored blood samples and informed
consents from all cancer cases available in all families, and
from all prospectively detected cases, and we in this way
were able to genetically test all prospectively detected cancer
cases, including all who had died before testing became
available. The timing of the current report reflects that the
testing as described below was completed in all families.
(1) Under a hypothesis of dominantly inherited breast or
breast–ovarian cancer in the families, all available
obligate carriers with breast or ovarian cancer, or
affected possible mutation carriers (as, for example,
an affected woman having no children), were Sanger
sequenced and MLPA tested.
(2) When no causative mutation in the family was found
this way, healthy obligate carriers (often males) were
Sanger sequenced and MLPA tested.
(3) When a causative BRCA mutation still had not been
excluded (typically when an affected mother was
dead and unavailable for testing), the individual
women at risk were tested for the Norwegian founder
mutations and in many cases subjected to Sanger
sequencing and MLPA testing as well.
(4) Daughters to affected cases demonstrated to not have
a BRCA mutation were not tested unless the family
history indicated a possibility of inherited cancer in
both the paternal and the maternal lineage. If so, the
family was considered two families and steps 1, 2
were conducted in both lineages and including testing
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of the at-risk daughters to males corresponding to step
3. As mentioned above, these at-risk daughters were
not included in the study, if their mothers had not had
cancer, but the procedure was part of identifying
mutation-carrying kindreds.
(5) All prospectively detected cancers were Sanger
sequenced and MLPA tested.
(6) All families in which a pathogenic mutation was
found in any member, were excluded from the study.
Families containing cancer cases suggestive of the Li–
Fraumeni (SBLA) syndrome [6] or the Cowden syndrome
[7] were tested for TP53 and PTEN mutations and the
mutation-carrying families were excluded from the present
study. Findings in mutation-carrying kindreds have been or
will be reported separately.
Follow-up implied referral to mammography at a breast
diagnostic center where, in addition, ultrasound, clinical
examination, fine needle aspiration cytology, core, and
excision biopsy were available without delay when indicated.
This report describes the combined results of these diagnostic
modalities in a clinical setting and is not an analysis of sen-
sitivities of the different modalities per se to demonstrate
cancer. Such analyses would not be meaningful in our clinical
series, where the result of the first examination was known to
the person interpreting the next examination in each patient.
For the current study, all cases had breast or ovarian
cancer prior to inclusion, or cancer demonstrated at the first
(prevalence) round, were excluded. All cancers after first
control were counted, including interval cancers, without
reference to how the cancer was detected. Each woman
was censored at the date for breast cancer demonstrated or
last examination, whichever came first. One patient was
counted once only, without notion of bilateral cancers. No
other cancer than breast cancer was scored as an event.
To compare our series with the Norwegian Cancer
Registry (www.kreftregisteret.no) as population controls,
we copied the cancer registry’s method and categorized the
observations into 5-year cohorts to determine the age-
specific incidence rates in each age group. Carcinoma
in situ was not scored as cancer. All women were scored
with respect to age groups for each year they were
observed. Differences between expected and observed
numbers of breast cancers were considered with v2 tests.
Annual incidence rates (AIRs) were calculated for each age
group separately, and were compared to similar groups
from the cancer registry as controls, arriving at standard-
ized incidence ratios (SIRs) with 95 % confidence intervals
(CIs). Based on the observed AIRs for each age group, the
cumulative incidences at different ages were calculated,
starting with cumulative incidence at age 25 years set to 0.
Relative cumulative incidence risks (RRs) compared to the
population controls were calculated.
The follow-up was censored December 2011. Data were
stored and computed inside our medical filing system CGEN
[8] and with use of TOAD and SYSTAT 13. No named
data were exported from the medical files. All patients had at
least one genetic counseling session, and all genetic testing
included written informed consent and were conducted
according to national legislation. The study was approved by
the Ethical review board (ref S02030) and The Norwegian
Data Inspectorate (ref 2001/2988-2). The present report is
one in a series to meet the request from The Norwegian
Parliament to report the results of our activities.
Results
A total of 7,748 persons were tested for BRCA mutations.
Deleterious mutations were found in 496 out of 2,118
(23 %) independent breast cancer kindreds tested.
From families without a demonstrable BRCA mutation
(‘the total series’), a total of 3,161 women met the inclusion
criteria and were observed for a total of 24,808 years (mean
follow-up time 7.9 years). Family data for categorizing into
subgroups based on family history was available for 2,962
patients (94 %), and among them 1,742 (59 %) met one or
more of the four criteria for subgroups. One-hundred and
seventy-two women had both two close relatives with breast
cancer = \55 years of age and four or more cases irre-
spective of age in their families. We found this number
insufficient to examine this group separately. The criterion
one breast cancer B50 years in family only was not over-
lapping any of the other criteria. Most (615 out of
860 = 72 %) of the cases with ovarian cancer in their fam-
ilies met more than one inclusion criteria. Because no excess
of cancers was demonstrated in the breast and ovarian cancer
families (Table 1) and because no very young onset breast
cancer case was seen in this group (Table 2), no subgroup
within this group was analyzed. This left us with the total
series and the four subgroups to examine further.
In the total series, 64 breast cancers were demonstrated,
compared to 34.0 expected (p \ 0.01; Table 1). In families
with 4 or more breast cancer cases, 9 cases were prospec-
tively demonstrated, compared to 3.7 expected (p \ 0.05).
In families with at least two cases B55 years at onset, 26
cases were demonstrated, compared to 9.2 expected
(p \ 0.05). In contrast, there was no excess of breast cancer
cases demonstrated neither in women with only one mother
or sister having had breast cancer at young age (11 dem-
onstrated compared to 7.8 expected, p [ 0.05) nor in the
families with both breast and ovarian cancer (14 demon-
strated compared to 8.7 expected, p [ 0.05). The same
differences were seen in all groups, when considering
cumulative risk at 50 years of age (Table 1). For both those
Breast Cancer Res Treat (2014) 144:607–614 609
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with only one mother or sister affected at young age, and for
those with ovarian cancer in the family, the cumulative risk
at age 40 was 0 observed, compared to 0.6 expected.
The AIRs for each age group are given in Table 2.
Based on these, cumulative incidences by age were cal-
culated in the total series to 1.0 % at age 40, 3.9 % at age
50, and 7.9 % at age 60, corresponding to RR of 2.9, 2.4,
and 2.0, respectively (Table 3).
Patients from families with two breast cancer
cases = \55 years of age had the highest cumulative
incidence rate at all ages, while those with only one early
onset cancer in the family had the lowest cumulative
incidence rate at all ages. Figure 1 demonstrates the
cumulative risk for each year from 25 to 60 years for all
groups.
Excluding all women with one relative = \50 years
only from the total series, cumulative risks at 40, 50 and
60 years were 1.5, 4.5 and 8.8 %, respectively, corre-
sponding to RR of 2.2 at age 60 years. As shown in Fig. 2,
for most ages women in this group had a cumulative
incidence similar to that of women 10 years older in the
general population.
We found the distribution curve in Fig. 1 compatible
with a limited subgroup within the group two cases in
family = \55 years having an early onset breast cancer
risk, which is compatible with a monogenic factor with
high penetrance and early onset.
More than one prospective case was diagnosed in nine
families: three cases in three families, two cases in six
families. Four of these families had four or more additional
breast cancer cases in the family, among which three had
two affected B55 years of age. All with two breast cancer
cases B55 years in the families had four additional cases in
the family. One of the nine families had one affected
additional case only and that one \50 years of age. In
seven of the nine families BRCA1/2, haplotyping was
possible and undertaken by use of intragenic and flanking
markers and no indication of linkage between BRCA1/2
haplotypes and breast cancer was found (data not shown).
The nine families were interpreted as in keeping with a
theory of highly penetrant inherited factors other than
mutated BRCA1/2 genes having caused disease in (some
of) the families. Extended genetic testing will be carried
out to search for highly penetrant genetic factors in all the
prospective cases reported here, pending resources to do so.
The lack of an increased risk to sisters of young onset
breast cancer cases was in conflict with expectation if
assuming recessive inheritance.
Discussion
Through the current report, we now have empirical figures
for breast cancer risk in breast cancer kindreds where a
BRCA mutation is not demonstrable: the cumulative inci-
dence rate for breast cancer in breast cancer kindreds
without a demonstrable genetic cause was 7.9 % = RR 2.0
at age 60 years. Those having only one early affected first
degree relative did not have increased risk for early onset
breast cancer. Restricting the analysis to women with two
ore more breast cancer cases in the family irrespective of
age, an RR at 60 years of 2.2 was obtained, corresponding
Table 1 Observed breast
cancers in total series and
subgroups based on family
history in woman \50 years, in
women 50–59 years, and in
total series compared to
expected compared to
population
(no result had 0.05\p\0.01),














25–49 17,873 36 16.8 21.9**
50–59 6,935 28 17.2 6.8**
25–59 24,808 64 34.0 26.4**
Four breast cancer cases or
more in family
(n = 314)
25–49 1,626 5 1.6 7.2**
50–59 836 4 2.1 1.8
25–59 2,462 9 3.7 7.7**
Two breast cancer
cases = \55 years or more
in family
(n = 865)
25–49 5,085 15 4.6 23.1**
50–59 1,819 11 4.5 9.3**
25–59 6,904 26 9.2 31.0**
One case only in family and that
case = \50 years
(n = 735)
25–49 4,669 6 4.2 0.8
50–59 1,474 5 3.7 0.5
25–59 6,143 11 7.8 1.3
Breast and ovarian cancer
in family
25–49 4,370 7 4.1 2.0
50–59 1,890 7 4.7 1.1
25–59 6,260 14 8.7 3.1
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to women 10 years older in the general population. The
highest RR at 60 years in any analyzed subgroup was 2.8.
Sanger sequencing and MLPA testing are insensitive to
detect medium-sized deletions [9]. However, the lack of an
increased risk for young onset breast cancer in families
with both breast and ovarian cancer, indicated that all or
close to all families with BRCA mutations had been iden-
tified and excluded from the study. Also, this indicated that
the excess of early onset breast cancers observed was not
caused by other high-penetrant genes for early onset breast
and ovarian cancer not tested for. As soon as resources
permit all prospectively detected cases will be examined
for all genes reportedly associated with breast cancer. If
this may not explain the findings, we may sequence all
protein-coding exons in all genes in all prospective cancer
cases to look for new genes causing breast cancer.
Compared to our series, a report by Metcalfe et al. [10]
from North America reported about twice our observed
AIRs. Besides their lower number of observation years
(9,109 compared to 24,808 in our study), there were
methodological differences between the studies: Metcalf
et al. used questionnaires and had a mean follow-up time of
6.1 years, implying they had no identified prevalence
round and were unable to remove prevalence cancers. We
recorded an overall prevalence rate of 0.60 % breast can-
cers at first planned mammography, which compared with
our observed overall AIR of 0.26 % represented 2.3 years
cumulative incidence, which is about one third of the
observation period reported by Metcalfe et al. We sub-
jected the families to more detailed genetic testing. Met-
calfe et al. did not test their prospectively detected cancers
for BRCA mutations. We assigned each woman to a 5 year
Table 3 Calculated cumulative risk for breast cancer by age based on observed annual incidence rates in 5-years cohorts in different groups and
in population (CTRL) as given in Table 2
Ages CTRL Total series Four breast cancer
cases in family
irrespective of age
Two breast cancer cases
B55 years in family
One breast cancer case




Cumulative risk RR Cumulative risk RR Cumulative risk RR Cumulative risk RR Cumulative risk RR
25 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000
30 0.0001 0.0000 0.0000 0.0000 0.0000 0.0000
35 0.0009 0.0055 6.1 0.0000 0.0119 13.4 0.0000 0.0000
40 0.0034 0.0100 2.9 0.0000 0.0193 5.7 0.0000 0.0000
45 0.0087 0.0179 2.1 0.0316 3.6 0.0364 4.2 0.0040 0.5 0.0040 0.5
50 0.0165 0.0388 2.4 0.0508 3.1 0.0579 3.5 0.0252 1.5 0.0286 1.7
55 0.0273 0.0541 2.0 0.0706 2.6 0.0839 3.1 0.0364 1.3 0.0460 1.7
60 0.0404 0.0789 2.0 0.0959 2.4 0.1138 2.8 0.0602 1.5 0.0640 1.6
RR relative risk compared to population
Fig. 1 Cumulative risk by age
in all cases with familial breast
cancer without a demonstrable
mutation (Total_series), in
women with four or more
affected relatives (four cases in
family), in women with two or
more affected
relatives = \55 years (two
cases B55), in women with both
breast and ovarian cancer in the
family (ovarian cancer in
family), in women where the
only affected relative was the
mother or one
sister = \50 years (one young
case B50 only in family), and in
population (cancer registry as
controls)
612 Breast Cancer Res Treat (2014) 144:607–614
123
cohort for each year observed. Metcalfe et al. grouped their
observations on age at baseline, implying that on average
more than half of the observation years in a woman included
as belonging to one age group, might have been recorded,
when she had become older and actually belonged to an
older age group. Also, the higher incidence rates in the
younger reported by Metcalfe et al. were in parallel to the
higher risk for young BRCA1 mutation carriers in North
America as compared to Poland and Norway [11, 12] and
may reflect environmentally caused differences between the
populations in Europe and North America. The difference
between our findings and those of Metcalfe et al. is, how-
ever, not significant to the discussion in this report on
moving toward personalized medicine. That notion is based
on the observations on risk for cancer in mutation carriers,
of the much lower risk for cancer in kindreds without a
demonstrable mutation, and that validation of family his-
tories in addition to what the patients may tell on-the-fly add
little to the risk estimates after testing.
After this study was completed and while the report was
written, other reports on findings in breast cancer kindreds
without demonstrated mutations have been published: two
follow-up studies on high-risk women with MRI (MARIBS
in UK and MRISC in Holland [13]) report prospective
findings in familial breast cancer, but to which degree the
familial breast cancer kindreds actually were BRCA tested
is unclear, and the reports were not organized to answer the
questions addressed in our study. The same may be noted
for two UK studies based on family history of breast cancer
[14, 15]. We look forward to see reports from other centers
focusing the questions addressed in this paper.
Speculating on the mechanisms having caused our
observations, we may mention: besides the notion that the
distribution curves may indicate a small subset with not
identified highly penetrant genetic factor(s), the findings
were as expected if assuming multiple genetic and/or envi-
ronmental factors having caused the family histories of
breast cancer. Non-random mating has been frequent in
Norway [3] and may give multifactorially caused clusters of
familial cancers with an increased recurrence risk in the next
generations compared to random mating. Which, if the
degree of inmating declines, will lead to decreased recur-
rence risk in the families in the future. Multifactorial inher-
itance may also explain that in those with one early affected
first degree relative only, the risk would be but moderately
increased and the next affected in the family would be
expected to have an age in-between index case and popula-
tion mean, which was the point estimate observed.
Conclusions
In breast cancer kindreds the presence/absence of a
BRCA1/2 mutation is the major determinant of risk for
breast cancer. The risk for breast cancer when a pathogenic
BRCA mutation is demonstrated is known. We here present
the first comprehensive empirical observations on risk for
breast cancer in families not having a demonstrable BRCA
mutation, which is what most genetic counseling sessions
are about when disclosing the results of BRCA testing. In
short, women in breast cancer kindreds without a demon-
strable BRCA mutation had about twice the risk of women
in the population to contract breast cancer at any age, with
the notion that having only one early affected mother or
sister was not associated with the increased risk for early
onset breast cancer and that in kindreds with multiple
young cases there may be other high-penetrant risk factors
than BRCA mutations to look for.
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